March 20, 2026
Clinical Updates
Arexvy (respiratory syncytial virus vaccine, adjuvanted) – Expanded indication
March 13, 2026 - GSK announced the FDA approval of Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted), for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
Clinical Updates
Cosentyx® (secukinumab) – Expanded indication
March 13, 2026 - Novartis announced the FDA approval of Cosentyx (secukinumab), for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older.
Drug Approvals
Nucynta® ER (tapentadol) – First-time authorized brand alternative
March 11, 2026 - Hikma launched an authorized brand alternative of Collegium’s Nucynta ER (tapentadol) extended-release tablets.
Drug Recalls - Availability
Insulet – Medical Device Correction of Omnipod® 5 Pods
March 13, 2026 - Insulet announced a voluntary medical device correction of Omnipod 5 Pods because specific lots may have a small tear in the internal tubing that delivers insulin. If this occurs, insulin may leak inside the Pod instead of being fully infused into the body as intended.